Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

298.25
-0.3300-0.11%
Volume:260.44K
Turnover:77.67M
Market Cap:14.24B
PE:-61.10
High:300.59
Open:298.25
Low:295.36
Close:298.58
52wk High:300.59
52wk Low:144.26
Shares:47.74M
Float Shares:47.20M
Volume Ratio:0.51
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8814
EPS(LYR):-2.9122
ROE:-7.52%
ROA:4.11%
PB:5.01
PE(LYR):-102.42

Loading ...

TD Cowen Sees Improving Demand for Contract Research Firms in Q2 2026

Reuters
·
Jul 09

Charles River Laboratories International Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Jul 08

Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220

MT Newswires Live
·
Jul 07

Coda Octopus Appoints Mark Kelly CFO Effective Aug. 3, 2026

Reuters
·
Jul 06

Charles River Laboratories International Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 02

Charles River Labs Director James C. Foster Disposes of 75,000 Shares Worth $16.88 Million

Reuters
·
Jul 02

Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating

MT Newswires Live
·
Jul 01

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

TIPRANKS
·
Jun 30

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

GlobeNewswire
·
Jun 30

Charles River Laboratories International Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 30

Charles River Laboratories International Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jun 27

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

GlobeNewswire
·
Jun 27

Charles River Laboratories International Inc. Stock Advances 5.2%, Outperforms Peers

Dow Jones
·
Jun 26

BTIG’s Brisebois Reiterates Buy on Aquestive Therapeutics, Calling Sell-Off Overdone After SPRY Payer Update and Highlighting Limited Scope of FDA CRL for Anaphylm

TIPRANKS
·
Jun 26

Movement Alert|Charles River Laboratories Rises 5.09% in Regular Trading, Morgan Stanley Upgrade and Positive Annual Report Signals Continue to Drive Momentum

Market Focus
·
Jun 25

Tanvex's US Unit Receives FDA Nod for TX05 Cancer Drug Biosimilar; Shares Drop 10%

MT Newswires Live
·
Jun 25

Charles River Laboratories International Inc. Stock Advances 8.3%, Outperforms Peers

Dow Jones
·
Jun 25

Movement Alert|Charles River Laboratories Rises 6.55% in Regular Trading, Morgan Stanley Upgrade and Positive Earnings Conference Signals Drive Rally

Market Focus
·
Jun 24

Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 23

Achieve Life Sciences CRL from FDA cites deficiencies at manufacturing facility

TIPRANKS
·
Jun 22